染色体微阵列分析在骨髓增生异常综合征诊疗中的应用

Application of chromosomal microarray in diagnosis and treatment of myelodysplastic syndrome

目的探讨染色体微阵列分析(CMA)在指导骨髓增生异常综合征(MDS)的诊断、治疗方式选择及预后判断中的意义。方法收集2016年3月至2020年6月收治的确诊及疑诊MDS并行CMA检查的36例患者的临床资料,对染色体核型、治疗及预后情况进行回顾性分析。结果确诊MDS患者27例,其中18例检测到恶性血液疾病相关的染色体改变,占66.67%。其中含Loss、LossMosaic 14例,占77.78%;含GainMosaic 3例,占16.67%;含UPD7例,占38.89%。27例患者中位总生存时间11(1~96)个月。相关性分析显示,患者的临床结局与性别(P<0.05),是否确诊MDS(P<0.01),危险度分级(中低危vs高危)(P=0.001)和CMA检测结果(P<0.01)具有相关性。logistic回归分析提示,CMA检测结果[阴性vs阳性,OR=2.565(95%CI1.059~4.345),P<0.05]是预测临床结局的独立危险因素。生存曲线分析显示CMA检测为阴性的患者总生存率优于CMA检测为阳性的患者,但两者生存曲线差异无统计学意义(P=0.051)。结论CMA检测对MDS诊断可以弥补染色体核型分析的不足,提升诊断率,同时可以为MDS患者提供更为准确的生存预测。

Objective To explore the significance of chromosomal microarray analysis(CMA)in guiding the diagnosis,treatment and prognosis of myelodysplastic syndrome(MDS).Methods The clinical data,karyotype analysis,treatment and prognosis of 36 patients with diagnosed or suspected MDS in the Department of Hematology of our hospital from March 2016 to June 2020 were analyzed retrospectively.All the patients were performed CMA check.Results Among the 27 patients with MDS,18 cases were detected chromosome changes related to malignant hematological diseases,accounting for 66.67%.There were 14 cases of loss and loss mosaic,accounting for 77.78%;Gainmosaic was found in 3 cases,accounting for 16.67%;7 cases with UPD,accounting for 38.89%.The median overall survival time of 27 patients was 11(1-96)months.Correlation analysis showed that the clinical outcome of patients was correlated with gender(P<0.05),diagnosis of MDS(P<0.01),risk grade(medium and low risk vs high risk)(P=0.001)and CMA test results(P<0.01).Logistic regression analysis showed that CMA test results(negative vs positive,OR=2.565[95%CI,1.059-4.345],P<0.05)were independent risk factors for predicting clinical outcomes.Survival analysis showed that the overall survival rate of patients with negative CMA was better than those with positive CMA,but there was no significant difference between the two survival curves(P<0.05).Conclusion CMA can make up for the deficiency of chromosome karyotype analysis and improve the diagnosis rate.CMA detection can provide more accurate survival prediction for patients with MDS.